

Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Demographic characteristics of the study population (N = 53 373) as stratified by psoriasis

	Psoriasis (N= 3 535)	No psoriasis (N= 49 838)
Sex (N=53 373)		
Female, <i>n</i> (%)	1 904 (53.9)	27 125 (54.4)
Male, <i>n</i> (%)	1 631 (46.1)	22 713 (45.6)
Age, years (SD) (N = 53 373)		
	57.3 (15.7)	53.7 (17.6)
Smoking (N= 53 137)		
Current daily, <i>n</i> (%)	465 (13.2)	3 933 (7.9)
No current daily, <i>n</i> (%)	3 056 (86.8)	45 683 (92.1)
Education (N= 53 024)		
<10 years, <i>n</i> (%)	408 (11.6)	5 396 (10.9)
10-12 years, <i>n</i> (%)	1 809 (51.5)	24 292 (49.1)
>12 years, <i>n</i> (%)	1 296 (36.9)	19 823 (40.4)
HLA-C*06:02-positive, <i>n</i> (%)*		
	248 (26.6)	1818 (11.7)
Psoriasis duration, years (SD) (N = 3 054)		
	26.7 (17.6)	NA
Current use of antihypertensive drugs, <i>n</i> (%) (N = 50 508)		
	999 (30.0)	10 943 (23.2)
Current use of cholesterol-lowering drugs, <i>n</i> (%) (N = 50 123)		
	749 (22.6)	7 556 (16.4)

*16 434 individuals were genotyped for rs4406273. Of these, 931 had psoriasis and 15 503 did not have psoriasis.

Abbreviations: SD, standard deviation; HLA, human leukocyte antigen.

Table SII. Demographic characteristics of the study population with psoriasis (N = 901)* as stratified by *HLA-C*06:02* status

	<i>HLA-C*06:02</i> positive (N = 237)	<i>HLA-C*06:02</i> negative (N = 664)
Sex (N= 901)		
Female, <i>n</i> (%)	129 (54.4)	347 (52.3)
Male, <i>n</i> (%)	108 (45.5)	317 (47.7)
Age, years (SD) (N= 901)		
	44.6 (15.6)	45.7 (16.6)
Smoking (N= 899)		
Current daily, <i>n</i> (%)	23 (9.7)	99 (15.0)
No current daily, <i>n</i> (%)	214 (90.3)	563 (85.1)
Education (N= 894)		
<10 years, <i>n</i> (%)	16 (6.80)	59 (8.8)
10-12 years, <i>n</i> (%)	112 (48.6)	345 (51.9)
>12 years, <i>n</i> (%)	102 (44.6)	261 (39.2)
Psoriasis duration, years (SD) (N = 803)		
	23.1 (14.6)	19.9 (14.4)
Current use of antihypertensive drugs, <i>n</i> (%) (N = 844)		
	36 (16.0)	107 (17.3)
Current use of cholesterol-lowering drugs, <i>n</i> (%) (N = 842)		
	23 (10.3)	77 (12.5)

*Individuals with psoriasis which were genotyped for rs4406273, excluding individuals of non-European descent and related individuals.

Abbreviations: SD, standard deviation; HLA, human leukocyte antigen.

Table SIII. Body composition parameters and cardiometabolic risk factors of the study population (N= 53 373) as stratified by psoriasis

	Psoriasis (N= 3 535)	No psoriasis (N= 49 838)
Body composition parameters*		
Percent body fat, % (95% CI)	33.3 (33.0, 33.6)	31.5 (31.4, 31.6)
Visceral fat area, cm^2 (95% CI)	138.4 (136.4, 140.3)	125.4 (125.0, 125.9)
Percent skeletal muscle mass, % (95% CI)	36.8 (36.6, 37.0)	37.8 (37.8, 37.9)
Percent soft lean mass, % (95% CI)	62.9 (62.6, 63.2)	64.5 (64.4, 64.6)
Percent fat free mass, % (95% CI)	66.7 (66.4, 67.0)	68.5 (68.4, 68.6)
Cardiometabolic risk factors†		
Body mass index, kg/m^2 (95% CI)	28.3 (28.1, 28.4)	27.3 (27.2, 27.3)
Waist circumference, cm (95% CI)	100.6 (100.1, 101.1)	97.4 (97.3, 97.5)
Systolic blood pressure, $mmHg$ (95% CI)	132.0 (131.4, 132.6)	131.1 (131.0, 131.3)
Diastolic blood pressure, $mmHg$ (95% CI)	74.1 (73.8, 74.4)	74.0 (73.9, 74.1)
Total cholesterol, $mmol/L$ (95% CI)	5.4 (5.3, 5.4)	5.3 (5.3, 5.3)
HDL cholesterol, $mmol/L$ (95% CI)	1.4 (1.4, 1.4)	1.4 (1.4, 1.4)
Triglycerides, $mmol/L$ (95% CI)	1.8 (1.8, 1.8)	1.7 (1.6, 1.7)
HbA1c, $mmol/mol$ (95% CI)	36.4 (36.1, 36.7)	35.3 (35.2, 35.3)
hsCRP, mg/L (95% CI)	3.1 (2.9, 3.3)	2.7 (2.7, 2.8)

*N = Range: 49 033-49 035.

†N = Range: 50 217-51 885.

All variables are standardized for age and reported as means (95% CI).

Abbreviations: kg, kilograms; cm, centimeter; HDL cholesterol, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; hsCRP, high-sensitivity C-reactive protein.

Table SIV. Body composition parameters and cardiometabolic risk factors of the study population with psoriasis (N = 901)€ as stratified by *HLA-C*06:02* status

	<i>HLA-C*06:02</i> positive (N = 237)	<i>HLA-C*06:02</i> negative (N = 664)
Body composition parameters*		
Percent body fat, % (95% CI)	31.9 (30.6, 33.1)	32.5 (31.7, 33.2)
Visceral fat area, cm^2 (95% CI)	132.0 (124.0, 139.9)	137.1 (132.4, 141.8)
Percent skeletal muscle mass, % (95% CI)	37.9 (37.1, 38.6)	37.5 (37.1, 37.9)
Percent soft lean mass, % (95% CI)	64.2 (62.9, 64.3)	63.6 (62.9, 64.3)
Percent fat free mass, % (95% CI)	68.1 (66.9, 69.4)	67.5 (66.8, 68.3)
Cardiometabolic risk factors†		
Body mass index, kg/m^2 (95% CI)	27.9 (27.3, 28.5)	28.5 (28.1, 28.9)
Waist circumference, cm (95% CI)	100.1 (98.1, 102.1)	102.0 (100.7, 103.2)
Systolic blood pressure, $mmHg$ (95% CI)	127.3 (125.0, 129.7)	127.1 (125.8, 128.4)
Diastolic blood pressure, $mmHg$ (95% CI)	74.6 (73.1, 76.0)	73.5 (72.8, 74.3)
Total cholesterol, $mmol/L$ (95% CI)	5.2 (5.0, 5.4)	5.3 (5.2, 5.4)
HDL cholesterol, $mmol/L$ (95% CI)	1.3 (1.3, 1.4)	1.3 (1.3, 1.4)
Triglycerides, $mmol/L$ (95% CI)	1.8 (1.6, 2.0)	1.9 (1.8, 2.0)
HbA1c, $mmol/mol$ (95% CI)	34.1 (33.3, 34.8)	34.6 (34.0, 35.1)
hsCRP, mg/L (95% CI)	2.6 (2.2, 3.0)	3.3 (2.9, 3.7)

€ Individuals with psoriasis which were genotyped for rs4406273, excluding individuals of non-European descent and related individuals.

*N = 860.

†N = Range: 875-899.

All variables are standardized for age and reported as means (95% CI).

Abbreviations: kg, kilograms; cm, centimeter; HDL cholesterol, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; hsCRP, high-sensitivity C-reactive protein.

Table SV. Prevalence ratio (PR) for comorbidities of the study population (N = 53 373) as stratified by psoriasis

	Psoriasis (N= 3535)	No psoriasis (N= 49 838)	Adjusted PR (95% CI)^a	Fully adjusted PR (95% CI)^b
Cardiovascular				
Myocardial infarction, <i>n</i> (%)	202 (6.0)	1664 (3.3)	1.54 (1.35, 1.76)	1.44 (1.26, 1.66)
Angina pectoris, <i>n</i> (%)	155 (4.6)	1308 (2.7)	1.55 (1.33, 1.82)	1.53 (1.30, 1.80)
Heart failure, <i>n</i> (%)	90 (2.7)	762 (1.5)	1.56 (1.27, 1.93)	1.54 (1.24, 1.92)
Atrial fibrillation, <i>n</i> (%)	259 (7.8)	2430 (4.9)	1.41 (1.25, 1.59)	1.35 (1.19, 1.52)
Apoplexia, <i>n</i> (%)	185 (5.5)	1506 (3.1)	1.63 (1.41, 1.88)	1.56 (1.34, 1.81)
Respiratory				
Asthma, <i>n</i> (%)	552 (16.4)	5612 (11.3)	1.51 (1.40, 1.64)	1.45 (1.34, 1.58)
Chronic obstructive pulmonary disease, <i>n</i> (%)	175 (5.2)	1227 (2.5)	1.89 (1.63, 2.20)	1.72 (1.47, 2.01)
Endocrine				
Diabetes, <i>n</i> (%)	336 (9.6)	2699 (5.4)	1.61 (1.45, 1.79)	1.49 (1.31, 1.69)
Hypothyroidism, <i>n</i> (%)	293 (8.8)	3072 (6.3)	1.32 (1.18, 1.47)	1.27 (1.14, 1.43)
Hyperthyroidism, <i>n</i> (%)	98 (3.0)	886 (1.8)	1.58 (1.29, 1.94)	1.54 (1.25, 1.90)
Other				
Migraine, <i>n</i> (%)	707 (21.0)	7622 (15.4)	1.41 (1.31, 1.50)	1.39 (1.30, 1.49)
Renal disease (non-UTI), <i>n</i> (%)	188 (5.6)	1584 (3.2)	1.63 (1.41, 1.89)	1.53 (1.31, 1.78)
Gout, <i>n</i> (%)	246 (7.3)	1778 (3.6)	1.83 (1.61, 2.07)	1.63 (1.44, 1.85)

∕ Individuals with psoriasis which were genotyped for rs4406273, excluding individuals of non-European descent and related individuals.

N = Range: 52 243-53 243.

^a Adjusted for age and sex.

^b Adjusted for age, sex, BMI, education, and smoking status.

Abbreviations: CI, confidence interval; UTI, urinary tract infection; BMI, body mass index.

Table SVI. Prevalence ratio (PR) for comorbidities of the study population with psoriasis (N = 901)ϕ as stratified by *HLA-C*06:02* status

	<i>HLA-C*06:02</i> positive (N =237)	<i>HLA-C*06:02</i> negative (N =664)	Adjusted PR (95%CI) ^a
Cardiovascular			
Myocardial infarction, <i>n</i> (%)	6 (2.7)	18 (2.8)	1.09 (0.37, 3.19)
Angina pectoris, <i>n</i> (%)	11 (4.9)	19 (3.0)	1.39 (0.59, 3.27)
Heart failure, <i>n</i> (%)	3 (1.3)	6 (0.9)	2.06 (0.15, 28.55)
Atrial fibrillation, <i>n</i> (%)	18 (8.0)	26 (4.1)	3.69 (1.85, 7.35)
Apoplexia, <i>n</i> (%)	7 (3.1)	21 (3.3)	0.84 (0.28, 2.54)
Respiratory			
Asthma, <i>n</i> (%)	31 (13.8)	116 (18.2)	0.80 (0.53, 1.21)
Chronic obstructive pulmonary disease, <i>n</i> (%)	7 (3.1)	18 (2.8)	1.23 (0.33, 4.51)
Endocrine			
Diabetes, <i>n</i> (%)	11 (4.8)	41 (6.2)	0.75 (0.34, 1.67)
Hypothyroidism, <i>n</i> (%)	12 (5.4)	41 (6.5)	0.94 (0.48, 1.87)
Hyperthyroidism, <i>n</i> (%)	5 (2.3)	12 (1.9)	1.24 (0.39, 3.99)
Other			
Migraine, <i>n</i> (%)	50 (22.3)	179 (28.1)	0.73 (0.54, 0.98)
Renal disease (non-UTI), <i>n</i> (%)	6 (2.7)	27 (4.2)	0.42 (0.13, 1.42)
Gout, <i>n</i> (%)	10 (4.5)	40 (6.3)	1.17 (0.57, 2.40)

ϕ Individuals with psoriasis which were genotyped for rs4406273, excluding individuals of non-European descent and related individuals.

N = Range: 754-784.

^a Adjusted for age, sex, BMI, smoking status, psoriasis disease duration and cryptic population structure by four principal components (PCs)

Abbreviations: CI, confidence interval; UTI, urinary tract infection; BMI, body mass index.